tetano
Editor, Senior Moderator
iScience
. 2023 May 19;26(5):106601.
doi: 10.1016/j.isci.2023.106601. Epub 2023 Apr 8.
The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein
Charles Zou[SUP] 1 [/SUP], Hojong Yoon[SUP] 1 2 [/SUP], Paul M C Park[SUP] 1 2 [/SUP], J J Patten[SUP] 3 [/SUP], Jesse Pellman[SUP] 1 2 [/SUP], Jeannie Carreiro[SUP] 1 2 [/SUP], Jonathan M Tsai[SUP] 1 2 [/SUP], Yen-Der Li[SUP] 1 2 [/SUP], Shourya S Roy Burman[SUP] 4 5 [/SUP], Katherine A Donovan[SUP] 4 5 [/SUP], Jessica Gasser[SUP] 1 2 [/SUP], Adam S Sperling[SUP] 1 2 6 [/SUP], Radosław P Nowak[SUP] 4 5 [/SUP], Eric S Fischer[SUP] 4 5 [/SUP], Robert A Davey[SUP] 3 [/SUP], Benjamin L Ebert[SUP] 1 2 7 [/SUP], Mikołaj Słabicki[SUP] 1 2 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hijacks multiple human proteins during infection and viral replication. To examine whether any viral proteins employ human E3 ubiquitin ligases, we evaluated the stability of SARS-CoV-2 proteins with inhibition of the ubiquitin proteasome pathway. Using genetic screens to dissect the molecular machinery involved in the degradation of candidate viral proteins, we identified human E3 ligase RNF185 as a regulator of protein stability for the SARS-CoV-2 envelope protein. We found that RNF185 and the SARS-CoV-2 envelope co-localize to the endoplasmic reticulum (ER). Finally, we demonstrate that the depletion of RNF185 significantly increases SARS-CoV-2 viral titer in a cellular model. Modulation of this interaction could provide opportunities for novel antiviral therapies.
Keywords: Cell biology; Virology.
. 2023 May 19;26(5):106601.
doi: 10.1016/j.isci.2023.106601. Epub 2023 Apr 8.
The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein
Charles Zou[SUP] 1 [/SUP], Hojong Yoon[SUP] 1 2 [/SUP], Paul M C Park[SUP] 1 2 [/SUP], J J Patten[SUP] 3 [/SUP], Jesse Pellman[SUP] 1 2 [/SUP], Jeannie Carreiro[SUP] 1 2 [/SUP], Jonathan M Tsai[SUP] 1 2 [/SUP], Yen-Der Li[SUP] 1 2 [/SUP], Shourya S Roy Burman[SUP] 4 5 [/SUP], Katherine A Donovan[SUP] 4 5 [/SUP], Jessica Gasser[SUP] 1 2 [/SUP], Adam S Sperling[SUP] 1 2 6 [/SUP], Radosław P Nowak[SUP] 4 5 [/SUP], Eric S Fischer[SUP] 4 5 [/SUP], Robert A Davey[SUP] 3 [/SUP], Benjamin L Ebert[SUP] 1 2 7 [/SUP], Mikołaj Słabicki[SUP] 1 2 [/SUP]
Affiliations
- PMID: 37095859
- PMCID: PMC10082641
- DOI: 10.1016/j.isci.2023.106601
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hijacks multiple human proteins during infection and viral replication. To examine whether any viral proteins employ human E3 ubiquitin ligases, we evaluated the stability of SARS-CoV-2 proteins with inhibition of the ubiquitin proteasome pathway. Using genetic screens to dissect the molecular machinery involved in the degradation of candidate viral proteins, we identified human E3 ligase RNF185 as a regulator of protein stability for the SARS-CoV-2 envelope protein. We found that RNF185 and the SARS-CoV-2 envelope co-localize to the endoplasmic reticulum (ER). Finally, we demonstrate that the depletion of RNF185 significantly increases SARS-CoV-2 viral titer in a cellular model. Modulation of this interaction could provide opportunities for novel antiviral therapies.
Keywords: Cell biology; Virology.